MarketPulse

cancer immunotherapy

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

ELISpot & FluoroSpot Market Set for 7.1% Growth Through 2031

Global ELISpot & FluoroSpot assay market to grow at 7.1% CAGR through 2031, driven by immunology research and personalized therapies.
MRKTMOBDXBIOBIO.B+1automationpersonalized medicine
GlobeNewswire Inc.GlobeNewswire Inc.··Mestag Therapeutics

Mestag Therapeutics Secures $40M to Advance FAP-Targeted Cancer Immunotherapy

Mestag Therapeutics closes $40M financing and appoints leadership to advance FAP-targeted cancer immunotherapy MST-0312 into Phase 1 clinical trials.
JNJclinical trialbispecific antibody
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

CTLA-4 Inhibitor Pipeline Expands With 50+ Candidates in Development Across 40+ Companies

Over 40 companies develop 50+ CTLA-4 inhibitor candidates for cancer immunotherapy. Recent FDA approvals and focus on combination strategies drive pipeline expansion.
BMYCELGrAZNIVBIYAGEN+1FDA approvalclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Checkpoint Inhibitor Market Analysis: 50+ Players Drive Immuno-Oncology Innovation Through 2026

Over 50 companies compete in the checkpoint inhibitor market with 60+ drug candidates in development. Major consolidation and innovation drive immuno-oncology growth through 2026.
BMYCELGrKYKOYRNAZclinical trialscompetitive landscape